Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells. / Marzec, Michal Tomasz; Liu, Xiaobin; Wysocka, Maria; Rook, Alain H.; Ødum, Niels; Wasik, Mariusz A.

In: PLoS ONE, Vol. 6, No. 9, e24849, 16.09.2011.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Marzec, MT, Liu, X, Wysocka, M, Rook, AH, Ødum, N & Wasik, MA 2011, 'Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells', PLoS ONE, vol. 6, no. 9, e24849. https://doi.org/10.1371/journal.pone.0024849

APA

Marzec, M. T., Liu, X., Wysocka, M., Rook, A. H., Ødum, N., & Wasik, M. A. (2011). Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells. PLoS ONE, 6(9), [e24849]. https://doi.org/10.1371/journal.pone.0024849

Vancouver

Marzec MT, Liu X, Wysocka M, Rook AH, Ødum N, Wasik MA. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells. PLoS ONE. 2011 Sep 16;6(9). e24849. https://doi.org/10.1371/journal.pone.0024849

Author

Marzec, Michal Tomasz ; Liu, Xiaobin ; Wysocka, Maria ; Rook, Alain H. ; Ødum, Niels ; Wasik, Mariusz A. / Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells. In: PLoS ONE. 2011 ; Vol. 6, No. 9.

Bibtex

@article{904f385b9b5c4ed4965f7810a01cea23,
title = "Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells",
abstract = "mTOR kinase forms the mTORC1 complex by associating with raptor and other proteins and affects a number of key cell functions. mTORC1 activates p70S6kinase 1 (p70S6K1) and inhibits 4E-binding protein 1 (4E-BP1). In turn, p70S6K1 phosphorylates a S6 protein of the 40S ribosomal subunit (S6rp) and 4E-BP1, with the latter negatively regulating eukaryotic initiation factor 4E (eIF-4E). MNK1 and MNK2 kinases phosphorylate and augment activity of eIF4E. Rapamycin and its analogs are highly specific, potent, and relatively non-toxic inhibitors of mTORC1. Although mTORC1 activation is present in many types of malignancies, rapamycin-type inhibitors shows relatively limited clinical efficacy as single agents. Initially usually indolent, CTCL displays a tendency to progress to the aggressive forms with limited response to therapy and poor prognosis. Our previous study (M. Marzec et al. 2008) has demonstrated that CTCL cells display mTORC1 activation and short-term treatment of CTCL-derived cells with rapamycin suppressed their proliferation and had little effect on the cell survival.",
author = "Marzec, {Michal Tomasz} and Xiaobin Liu and Maria Wysocka and Rook, {Alain H.} and Niels {\O}dum and Wasik, {Mariusz A.}",
year = "2011",
month = sep,
day = "16",
doi = "10.1371/journal.pone.0024849",
language = "English",
volume = "6",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

RIS

TY - JOUR

T1 - Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells

AU - Marzec, Michal Tomasz

AU - Liu, Xiaobin

AU - Wysocka, Maria

AU - Rook, Alain H.

AU - Ødum, Niels

AU - Wasik, Mariusz A.

PY - 2011/9/16

Y1 - 2011/9/16

N2 - mTOR kinase forms the mTORC1 complex by associating with raptor and other proteins and affects a number of key cell functions. mTORC1 activates p70S6kinase 1 (p70S6K1) and inhibits 4E-binding protein 1 (4E-BP1). In turn, p70S6K1 phosphorylates a S6 protein of the 40S ribosomal subunit (S6rp) and 4E-BP1, with the latter negatively regulating eukaryotic initiation factor 4E (eIF-4E). MNK1 and MNK2 kinases phosphorylate and augment activity of eIF4E. Rapamycin and its analogs are highly specific, potent, and relatively non-toxic inhibitors of mTORC1. Although mTORC1 activation is present in many types of malignancies, rapamycin-type inhibitors shows relatively limited clinical efficacy as single agents. Initially usually indolent, CTCL displays a tendency to progress to the aggressive forms with limited response to therapy and poor prognosis. Our previous study (M. Marzec et al. 2008) has demonstrated that CTCL cells display mTORC1 activation and short-term treatment of CTCL-derived cells with rapamycin suppressed their proliferation and had little effect on the cell survival.

AB - mTOR kinase forms the mTORC1 complex by associating with raptor and other proteins and affects a number of key cell functions. mTORC1 activates p70S6kinase 1 (p70S6K1) and inhibits 4E-binding protein 1 (4E-BP1). In turn, p70S6K1 phosphorylates a S6 protein of the 40S ribosomal subunit (S6rp) and 4E-BP1, with the latter negatively regulating eukaryotic initiation factor 4E (eIF-4E). MNK1 and MNK2 kinases phosphorylate and augment activity of eIF4E. Rapamycin and its analogs are highly specific, potent, and relatively non-toxic inhibitors of mTORC1. Although mTORC1 activation is present in many types of malignancies, rapamycin-type inhibitors shows relatively limited clinical efficacy as single agents. Initially usually indolent, CTCL displays a tendency to progress to the aggressive forms with limited response to therapy and poor prognosis. Our previous study (M. Marzec et al. 2008) has demonstrated that CTCL cells display mTORC1 activation and short-term treatment of CTCL-derived cells with rapamycin suppressed their proliferation and had little effect on the cell survival.

U2 - 10.1371/journal.pone.0024849

DO - 10.1371/journal.pone.0024849

M3 - Journal article

C2 - 21949767

VL - 6

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 9

M1 - e24849

ER -

ID: 35354367